STOCK TITAN

REGEN BIOPHARMA INC - RGBP STOCK NEWS

Welcome to our dedicated page for REGEN BIOPHARMA news (Ticker: RGBP), a resource for investors and traders seeking the latest updates and insights on REGEN BIOPHARMA stock.

Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) is a pioneering biotechnology company based in La Mesa, California, specializing in the development of small molecule therapies for the treatment of cancer and autoimmune disorders. Founded in 2012, the company focuses on innovative immunology and immunotherapy solutions, rapidly advancing novel technologies from pre-clinical stages through Phase I and II clinical trials.

At the core of Regen BioPharma's research is the NR2F6 small molecule activator, which plays a crucial role in immune cell modulation for oncology and autoimmune diseases. The company's pipeline includes mRNA and small molecule therapies aimed at providing groundbreaking treatments for these debilitating conditions.

Regen BioPharma's recent achievements include significant progress in validating its DuraCAR CAR-T cell therapeutic, designed to target CD19 and NR2F6. Initial in vitro experiments have shown promising results, with subsequent studies revealing unexpected outcomes that could pave the way for developing new autoimmune-suppressive T cell therapies. The company has engaged independent Contract Research Organizations (CROs) to verify these findings, ensuring robust and reproducible data.

The company's commitment to advancing its research is further demonstrated by its ongoing efforts in the autoimmune therapeutic category. Regen BioPharma is poised to initiate a Phase I clinical trial, leveraging its deep intellectual property portfolio and novel technologies.

Regen BioPharma's strategy extends to partnerships and collaborations with leading scientific experts and institutions. This approach not only accelerates the development of their therapies but also positions the company as a significant player in the biotech industry.

For more information, visit Regen BioPharma, Inc.

Rhea-AI Summary
Regen BioPharma is developing a genetic approach to regulating NR2F6 levels in human T cells. They have received potentially useful data from a contract research organization, which showed successful creation of T cells expressing siRNA for NR2F6. The company is awaiting qRT-PCR test results to determine the potential for cancer and autoimmune disorder treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
CAR-T Cells Created
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.57%
Tags
none
-
Rhea-AI Summary
Goldman Small Cap Research publishes research report on Regen BioPharma, Inc. (OTCPK:RGBP)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
Rhea-AI Summary
Regen BioPharma, Inc. to present at the Emerging Growth Conference, discussing recent S-1 filing and equity facility. CEO to provide updates on scientific programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences acquisition
-
Rhea-AI Summary
Regen BioPharma completes initial design and testing, but unexpected results in experiments may impact future therapy development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.07%
Tags
none
-
Rhea-AI Summary
Regen BioPharma, Inc. to present at the Emerging Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
conferences acquisition
Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) is set to present at the Emerging Growth Conference on February 22, 2023, from 2:40 to 2:50 PM Eastern Time. This live event will provide a platform for interaction with CEO Dr. David Koos, where shareholder questions will be addressed. Key discussion points include updates on a pending reverse stock split and future financing plans. Registration is available for real-time participation and an archived webcast will also be accessible post-event. The conference showcases companies in growth sectors and aims to connect them with investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) invites investors to its live presentation at the Emerging Growth Conference on February 8, 2023. The interactive session will provide insights on the company's strategic plans, drug pipeline, and upcoming 1-for-1500 reverse stock split effective March 6, 2023. CEO Dr. David Koos will address shareholder questions during the event.

Regen BioPharma is focused on advancing therapies for cancer and autoimmune disorders through pre-clinical and Phase I/II clinical trials. The conference presentation is scheduled from 2:20 - 2:50 PM Eastern Time. An archived webcast will be available post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.65%
Tags
conferences
-
Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) will present at the Emerging Growth Conference on January 25, 2023, from 3:30 - 3:40 PM Eastern. This online event allows shareholders and the investment community to engage with CEO Dr. David Koos in real time. The company aims to update stakeholders on recent intellectual property and respond to questions during the session. Attendees can register for the event at the [official registration link](https://goto.webcasts.com/starthere.jsp?ei=1575092&tp_key=9111d280ed&sti=rgbp). An archived version of the presentation will also be available on [EmergingGrowth.com](http://EmergingGrowth.com).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
conferences
Rhea-AI Summary

Regen BioPharma, Inc. (OTC PINK: RGBP, RGBPP) has filed a provisional patent application focused on using survivin-engineered dendritic cells and exosomes to enhance anti-cancer immunity. This approach aims to improve the immune system's ability to target and destroy survivin-expressing tumor cells while sparing healthy tissue. The company draws on prior work with DCellVax for breast cancer treatment and is positioned to diversify its portfolio in the expanding immunotherapy market, which is projected to reach $100 billion globally. CEO David Koos emphasized the potential for new revenue streams through this innovative strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
none

FAQ

What is the current stock price of REGEN BIOPHARMA (RGBP)?

The current stock price of REGEN BIOPHARMA (RGBP) is $0.0575 as of December 23, 2024.

What is the market cap of REGEN BIOPHARMA (RGBP)?

The market cap of REGEN BIOPHARMA (RGBP) is approximately 1.1M.

What is Regen BioPharma, Inc.?

Regen BioPharma, Inc. is a biotechnology company focused on developing small molecule therapies for treating cancer and autoimmune disorders.

What is the NR2F6 small molecule?

The NR2F6 small molecule is a key component in Regen BioPharma's research, aimed at modulating immune cells for oncology and autoimmune treatments.

Where is Regen BioPharma, Inc. based?

Regen BioPharma, Inc. is based in La Mesa, California.

When was Regen BioPharma, Inc. founded?

Regen BioPharma, Inc. was founded in 2012.

What are the recent achievements of Regen BioPharma?

Recent achievements include progress in validating the DuraCAR CAR-T cell therapeutic and potential developments in autoimmune-suppressive T cell therapies.

What is the focus of Regen BioPharma's current projects?

The current projects focus on mRNA and small molecule therapies for cancer and autoimmune disorders, including the DuraCAR CAR-T cell therapeutic.

Who is the CEO of Regen BioPharma, Inc.?

The CEO of Regen BioPharma, Inc. is Dr. David Koos.

What is the significance of the DuraCAR CAR-T cell therapeutic?

The DuraCAR CAR-T cell therapeutic is designed to target CD19 and NR2F6, with potential applications in cancer and autoimmune disorder treatments.

How does Regen BioPharma ensure the validity of its research?

Regen BioPharma engages independent Contract Research Organizations (CROs) to verify findings and ensure robust and reproducible data.

How can I get more information about Regen BioPharma, Inc.?

For more information, visit their official website at Regen BioPharma, Inc..

REGEN BIOPHARMA INC

OTC:RGBP

RGBP Rankings

RGBP Stock Data

1.13M
10.52M
0.01%
Biotechnology
Healthcare
Link
United States of America
La Mesa